About Apellis Pharmaceuticals
Apellis Pharmaceuticals is a company based in Crestwood (United States) founded in 2008 by Pascal Deschatelets and Cedric Francois was acquired by Biogen in March 2026. Apellis Pharmaceuticals has raised $213.21 million across 13 funding rounds from investors including Biogen, HHS and Eight Roads Ventures. The company has 710 employees as of December 31, 2024. Apellis Pharmaceuticals offers products and services including Complement Science Therapies and Clinical Trial Programs. Apellis Pharmaceuticals operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Crestwood, United States
- Employees 710 as on 31 Dec, 2024
- Founders Pascal Deschatelets, Cedric Francois
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Apellis Pharmaceuticals, Inc.
-
Annual Revenue
$781.37 M (USD)97.02as on Dec 31, 2024
-
Net Profit
-$197.88 M (USD)62.57as on Dec 31, 2024
-
EBITDA
-$163.18 M (USD)68.34as on Dec 31, 2024
-
Total Equity Funding
$213.21 M (USD)
in 13 rounds
-
Latest Funding Round
$328.9 M (USD), Post-IPO
May 07, 2020
-
Investors
Biogen
& 13 more
-
Employee Count
710
as on Dec 31, 2024
-
Acquired by
Biogen
(Mar 31, 2026)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Apellis Pharmaceuticals
Apellis Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol APLS in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Apellis Pharmaceuticals
Apellis Pharmaceuticals offers a comprehensive portfolio of products and services, including Complement Science Therapies and Clinical Trial Programs.
Treatments targeting C3 for rare diseases and atrophy.
Pipeline for developing innovative disease treatments.
People of Apellis Pharmaceuticals
Unlock access to complete
Leadership Team
41 people
Software Development Team
21 people
Legal and Compliance
15 people
Senior Team
14 people
Finance and Accounting
11 people
Operations Team
9 people
Product Management Team
4 people
Sales and Marketing
3 people
Unlock access to complete
Funding Insights of Apellis Pharmaceuticals
Apellis Pharmaceuticals has successfully raised a total of $213.21M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $328.9 million completed in May 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Apellis Pharmaceuticals
Apellis Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Biogen, HHS and Eight Roads Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sectoral Asset Management is focused on global healthcare investment.
|
Locked | Locked | Locked | |
|
Biotech funding, drug development support, and investment in life sciences.
|
Locked | Locked | Locked | |
|
Venture capital and private equity firm
|
Locked | Locked | Locked |
Investor details for Apellis Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Apellis Pharmaceuticals
Investment portfolio details for Apellis Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Apellis Pharmaceuticals
Detailed financials for Apellis Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Apellis Pharmaceuticals Comparisons
Peer comparison for Apellis Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Apellis Pharmaceuticals
Apellis Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Plasma-based biologics are developed for immune deficiency and infectious diseases.
|
|
| Locked | Locked | Locked |
Small molecule protein degraders are developed for various disorders.
|
|
| Locked | Locked | Locked |
Immunotherapeutics for cancer and other diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases.
|
Detailed competitors of Apellis Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Apellis Pharmaceuticals
Complete news archive for Apellis Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Apellis Pharmaceuticals
Apellis Pharmaceuticals was founded in 2008.
Apellis Pharmaceuticals is headquartered in Crestwood, United States.
Cedric Francois is the current CEO of Apellis Pharmaceuticals. They have also founded this company.
Apellis Pharmaceuticals is a funded company, having raised a total of $213.21M across 13 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Apellis Pharmaceuticals is 710.
Annual revenue of Apellis Pharmaceuticals is $781.37M as on Dec 31, 2024.
Apellis Pharmaceuticals was founded in 2008 and is headquartered in Crestwood, United States. Therapies are developed by the company to address autoimmune and inflammatory conditions through modulation of the complement system, a key immune component. Programs are focused on ophthalmology, nephrology, hematology, and neurology, with operations centered in the biotechnology sector.
Apellis Pharmaceuticals's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
Apellis Pharmaceuticals offers Complement Science Therapies and Clinical Trial Programs.
Yes, Apellis Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol APLS.
Apellis Pharmaceuticals has 14 investors. Key investors include Biogen, HHS, Eight Roads Ventures, Clough Capital Partners, and Sectoral Asset Management.
The ticker symbol of Apellis Pharmaceuticals is APLS on NASDAQ.